-
Company Profile
![]()
Les Laboratoires Servier SAS – Company Profile
Les Laboratoires Servier SAS (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company's portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. It invests a substantial amount of revenue in R&D, particularly in France and Hungary. The company also provides digital therapeutic solutions through its e-health...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Taletrectinib Adipate in Brain Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Taletrectinib Adipate in Brain Tumor Drug Details: Taletrectinib (DS-6051b/AB-106) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Drug To Target Pd L1 And Cd137 For Solid Tumors in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Drug To Target Pd L1 And Cd137 For Solid Tumors in Solid Tumor Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Diphtheria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Diphtheria Drug Details:Pediatric DTaP vaccine is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AD-113 in Obstructive Sleep Apnea
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AD-113 in Obstructive Sleep Apnea Drug Details: AD-113 is under development for the treatment of obstructive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ARQ-154 in Psoriasis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ARQ-154 in Psoriasis Drug Details:ARQ-154 is under development for the treatment of seborrheic dermatitis, scalp psoriasis and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SCO-240 in Gall Stone
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SCO-240 in Gall StoneDrug Details:SCO-240 is under development for the treatment of diabetes, cholelithiasis, gall stone,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CD19 Antibody in Autoimmune Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CD19 Antibody in Autoimmune DisordersDrug Details:Monoclonal antibody is under development for the treatment of autoimmune diseases....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vorasidenib Citrate in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vorasidenib Citrate in Myelodysplastic Syndrome Drug Details: Vorasidenib (AG-881) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vorasidenib Citrate in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vorasidenib Citrate in Refractory Acute Myeloid Leukemia Drug Details: Vorasidenib (AG-881) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vorasidenib Citrate in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vorasidenib Citrate in Relapsed Acute Myeloid Leukemia Drug Details: Vorasidenib (AG-881) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ninerafaxstat in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ninerafaxstat in Coronary Artery Disease (CAD) (Ischemic Heart Disease)Drug Details:ninerafaxstat is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – S-095029 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-095029 in Solid Tumor Drug Details: S-095029 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BI-685509 in Systemic Sclerosis (Scleroderma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BI-685509 in Systemic Sclerosis (Scleroderma) Drug Details: BI-685509 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMMH-010 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMMH-010 in Non-Small Cell Lung Cancer Drug Details: IMMH-010 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-6665 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-6665 in Refractory Acute Myeloid Leukemia Drug Details:JNJ-6665 is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-6665 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-6665 in Relapsed Acute Myeloid Leukemia Drug Details:JNJ-6665 is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBB-167 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BGBB-167 in Colorectal Cancer Drug Details:BGBB-167 is under development for the treatment of advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IBI-345 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IBI-345 in Gastric Cancer Drug Details:IBI-345 is under development for the treatment of hematological tumors and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JDQ-443 in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JDQ-443 in Small-Cell Lung Cancer Drug Details:JDQ-443 is under development for the treatment of advanced solid...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.